The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada.

J Mark FitzGeraldJ Mark FitzGeraldPaul M O'ByrneMena SolimanNiroshan SriskandarajahColin VicenteSarowar Muhammad Golam

Published in: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology (2021)

As-needed budesonide-formoterol is a cost-saving option for the treatment of mild asthma from the perspective of the Canadian public payer compared with low-dose maintenance ICS plus as-needed SABA.

Keyphrases

low dose
chronic obstructive pulmonary disease
lung function
high dose
allergic rhinitis
cystic fibrosis
healthcare
mental health
stem cells
emergency department
combination therapy
bone marrow
adverse drug
replacement therapy